Overview

  • Product nameAnti-C9 antibody
    See all C9 primary antibodies
  • Description
    Rabbit polyclonal to C9
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 500 to the C-terminus of Human C9.

    (Peptide available as ab94838.)

  • Positive control
    • This antibody gave a positive signal in the following tissue lysates: Human placenta; Human plasma total protein

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 1% BSA, PBS. pH 7.4
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products

Applications

Our Abpromise guarantee covers the use of ab67040 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1 µg/ml. Detects a band of approximately 74 kDa (predicted molecular weight: 63 kDa).
    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionConstituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
    • Tissue specificityPlasma.
    • Involvement in diseaseDefects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
    • Sequence similaritiesBelongs to the complement C6/C7/C8/C9 family.
      Contains 1 EGF-like domain.
      Contains 1 LDL-receptor class A domain.
      Contains 1 MACPF domain.
      Contains 1 TSP type-1 domain.
    • Post-translational
      modifications
      Thrombin cleaves factor C9 to produce C9a and C9b.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore.
    • Information by UniProt
    • Database links
    • Alternative names
      • C9 antibody
      • C9 deficiency antibody
      • C9 deficiency with dermatomyositis antibody
      • CO9_HUMAN antibody
      • Complement component 9 antibody
      • Complement component 9 deficiency antibody
      • Complement component C9 antibody
      • Complement component C9b antibody
      see all

    Anti-C9 antibody images

    • All lanes : Anti-C9 antibody (ab67040) at 1 µg/ml

      Lane 1 : Human Plasma Total Protein Lysate
      Lane 2 : Human placenta tissue lysate - total protein (ab29745)

      Lysates/proteins at 10 µg per lane.

      Secondary
      Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
      Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 63 kDa
      Observed band size : 74 kDa (why is the actual band size different from the predicted?)
      Additional bands at : 40 kDa. We are unsure as to the identity of these extra bands.

      Exposure time : 16 minutes

    References for Anti-C9 antibody (ab67040)

    ab67040 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab67040.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"